Patient Partners

Click here to see a PDF of this page

MicroMass Communications

Company Profile

Patient-centricity. These words don't just describe our offerings. They are how we've operated for over 20 years. As an agency with an expertise in human health behavior, we build patient marketing programs that are fundamentally different. Going beyond messages and education, we deploy evidence-based techniques from the behavioral sciences to engage patients in a meaningful way — and drive optimal outcomes.

Core Capabilities

Our programs address the complexities of behavior with strategies like motivational interviewing, cognitive behavioral techniques, and problem solving.  It is this seamless integration of science, art, marketing and technology that allows us to meet brand objectives, drive lasting behavior change, and engage people with products.

Services and Offerings

We specialize in developing patient support, engagement, and relationship marketing programs. Some recent efforts include:

• Time2Focus, a proprietary mobile app that helps patients build problem-solving skills to manage type 2 diabetes.  Using gamification principles, the experience guides patients through skill-building activities related to real-world scenarios, including monitoring glucose, staying active, and healthy eating. The app is currently being tested in a clinical trial and will be available late 2014. We plan to apply this platform to other chronic diseases in 2015.
• Relationship marketing programs to help people with HCV work toward a cure
• Toolkits to help oncology nurses more effectively counsel patients with bone metastases
• An online community for patients living with pulmonary arterial hypertension
• A disease education program to support cancer patients taking oral oncology therapies

Our mission—to improve health outcomes through the application of behavioral science—has spread beyond programs and campaigns to gain the attention of organizations who want to enhance their capability in behavior change. Recently, we added behavioral consulting and clinical educator team tools and trainings to our offerings.

What does patient-centricity mean to you and is the industry doing enough to fulfill the needs of patients?

We think first about people, not products, and address human needs to achieve better outcomes. For Pharma, this means viewing success in the context of real world results, rather than clinical benchmarks, and putting the patient at the center of drug development and commercialization.  For this to occur, Pharma needs to help patients build the skills they need to manage their diseases more effectively, thus completing an evolution from a marketing playbook built around a brand to one that actively engages patients in their care.

Address: 11000 Regency Parkway, Suite 300, Cary, NC 27518 Phone: 919-851-3182
Website: www.micromass.com New Business Contact: Jude Kelly, Director of ­Business Development, jude.kelly@micromass.com or 919-256-2401 Year Founded: 1994 Employees: 68 Holding Company: N/A Sample Clients: GSK, Gilead, Novo Nordisk, Sanofi, United Therapeutics, Amgen, Merck

Page 5 of 7
You must be a registered member of MMM to post a comment.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.